Скачать или смотреть CREXONT (carbidopa and levodopa) extended-release capsules has transformed innovation into duration

CREXONT Mechanism of Action (MOA) For patients and caregivers.

For the first time in Parkinson’s disease, an oral therapy was designed to target where levodopa is best absorbed the proximal small intestine-making CREXONT the oral CD/LD formulation with the longest-lasting LD plasma concentration ¹, ², ³, *, **

References: *Exact site and duration of absorption are unknown.

**Based on the time that LD plasma levels were above 50% of Cmax.⁴

1. Hauser RA, Espay AJ, Ellenbogen AL, et al. IPX203 vs immediate-release carbidopa- levodopa for the treatment of motor fluctuations in Parkinson disease: the RISE-PD randomized clinical trial. JAMA Neurol. 2023;80(10):1062-1069.

2. LeWitt PA. Levodopa therapy for Parkinson’s disease: pharmacokinetics and pharmacodynamics. Mov Disord. 2015;30(1):64-72.

3. Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson’s disease: current status and future developments. Curr Neuropharmacol. 2018;16(8):1239-1252.

4. Modi NB, Mittur A, Rubens R, Khanna S, Gupta S. Single-dose pharmacokinetics and pharmacodynamics of IPX203 in patients with advanced Parkinson disease: a comparison with immediate-release carbidopa-levodopa and with extended-release carbidopa-levodopa capsules. Clin Neuropharmacol. 2019;42(1):4-8